Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Trial details
- Registry ID
- NCT02859961
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Leronlimab
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961 | CytoDyn, Inc. | Phase 2, Phase 3 | Completed | 2020-09-16Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |